Capsaicin dermal patch - NeurogesX

Drug Profile

Capsaicin dermal patch - NeurogesX

Alternative Names: 8% capsaicin patch - NeurogesX; Capsaicin; NGX-4010; Qutenza; Transacin; Transdolor™ Pain Treatment System

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator NeurogesX
  • Developer Astellas Pharma Europe Ltd; NeurogesX
  • Class Antipruritics; Catechols; Local anaesthetics; Monounsaturated fatty acids; Non-opioid analgesics; Polyunsaturated alkamides; Small molecules
  • Mechanism of Action Substance P inhibitors; TRPV1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuropathic pain; Postherpetic neuralgia
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Neuropathic pain; Postherpetic neuralgia
  • Registered Diabetic neuropathies
  • No development reported Postoperative pain

Most Recent Events

  • 12 Dec 2016 Astellas enters into a definitive agreement with Grünenthal for transfer of exclusive rights to Qutenza in Europe, Middle East and Africa
  • 29 Apr 2016 Biomarkers information updated
  • 19 Nov 2015 Safety and efficacy data from the head-to-head ELEVATE trial for peripheral Neuropathic pain released by Astellas
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top